Breast Surgery Practice Questions

Q: Which type of breast cancer has the best prognosis?

Mucinous carcinoma. **Explanation:** The prognosis of breast cancer is primarily determined by its histological subtype, grade, and molecular markers. Among the options provided, **Mucinous (Colloid) carcinoma** carries the best prognosis. 1. **Mucinous Carcinoma (Correct):** This is a rare subtype (approx. 2% of cases) characterized by clusters of tumor cells floating in large pools of extracellular mucin. It typically occurs in older women, is slow-growing, and has a very low incidence of axillary lymph node metastasis. When it presents in its "pure" form, the 10-year survival rate exceeds 90%. 2. **Medullary Carcinoma:** While it generally has a better prognosis than standard invasive ductal carcinoma (IDC) due to its well-circumscribed nature and heavy lymphocytic infiltrate, it is still more aggressive than the pure mucinous subtype. It is often associated with BRCA1 mutations. 3. **Invasive Ductal Carcinoma (IDC):** This is the most common type of breast cancer (70-80%). It has a highly variable prognosis but is generally more aggressive than mucinous or medullary types because it lacks the favorable histological features that limit spread. 4. **Lobular Carcinoma:** Invasive lobular carcinoma (ILC) often presents with a "single-file" pattern (Indian file). While its prognosis is similar to IDC, it is frequently multifocal and bilateral, making surgical management more complex. **NEET-PG High-Yield Pearls:** * **Best Prognosis overall:** Tubular carcinoma (often >95% 10-year survival). * **Worst Prognosis:** Inflammatory breast cancer (T4d). * **Molecular Subtype with best prognosis:** Luminal A (ER/PR positive, HER2 negative, low Ki-67). * **Paget’s Disease of the nipple:** Usually associated with an underlying DCIS or invasive carcinoma.

Q: Which of the following medications should NOT be given in cyclic mastalgia?

Estrogen. **Explanation:** **Cyclic mastalgia** is characterized by breast pain that fluctuates with the menstrual cycle, typically peaking during the luteal phase. The underlying pathophysiology is linked to hormonal imbalances, specifically an **excess of estrogen** or a relative deficiency of progesterone, leading to ductal proliferation and interstitial edema. **Why Estrogen is the correct answer:** Since cyclic mastalgia is often exacerbated by high levels of circulating estrogen, administering **Estrogen (Option D)** would worsen the condition rather than treat it. Estrogen promotes breast tissue proliferation and fluid retention, which are the primary drivers of cyclic pain. **Analysis of Incorrect Options:** * **Evening Primrose Oil (Option A):** Contains gamma-linolenic acid (GLA). It is often used as a first-line non-hormonal treatment to restore the balance of essential fatty acids, which may reduce breast sensitivity to hormones. * **Danazol (Option B):** An antigonadotropin that inhibits the pituitary-ovarian axis. It is the only FDA-approved drug for severe mastalgia, though its use is limited by androgenic side effects (weight gain, acne, hirsutism). * **Tamoxifen (Option C):** A Selective Estrogen Receptor Modulator (SERM). It blocks estrogen receptors in the breast and is highly effective for refractory mastalgia, though it is used off-label. **NEET-PG High-Yield Pearls:** 1. **First-line management:** Reassurance and a well-fitted sports bra (effective in 70-80% of cases). 2. **First-line pharmacological agent:** Topical NSAIDs (e.g., Diclofenac gel). 3. **Gold standard for severe cases:** Danazol (but Tamoxifen is often preferred clinically due to a better side-effect profile). 4. **Bromocriptine:** Previously used but now avoided due to significant side effects.

Q: Which of the following is an increased risk factor for carcinoma of the breast?

BRCA1 mutation. **Explanation:** The correct answer is **A. BRCA1 mutation**. **1. Why BRCA1 mutation is correct:** BRCA1 (Brest Cancer Gene 1) is a tumor suppressor gene located on chromosome 17q. It plays a critical role in DNA repair via homologous recombination. A germline mutation in this gene leads to genomic instability, significantly increasing the lifetime risk of developing breast cancer (up to 65-80%) and ovarian cancer (up to 40%). It is the most significant genetic risk factor among the options provided. **2. Why the other options are incorrect:** * **B. Breastfeeding:** This is a **protective factor**. Prolonged lactation reduces the total number of ovulatory cycles and promotes the differentiation of mammary epithelial cells, thereby lowering the risk of breast cancer. * **C. Multiparity:** Having multiple children is **protective**. Early first full-term pregnancy (before age 20) and high parity reduce lifetime estrogen exposure. Conversely, *nulliparity* (having no children) is a known risk factor. * **D. Smoking:** While smoking is a major risk factor for many malignancies (like lung and bladder cancer), its direct association with breast cancer is less definitive compared to hormonal and genetic factors. In the context of NEET-PG, it is generally considered a "weak" or inconsistent risk factor compared to a high-penetrance mutation like BRCA1. **High-Yield Clinical Pearls for NEET-PG:** * **BRCA1 vs. BRCA2:** BRCA1 is on Chromosome **17**; BRCA2 is on Chromosome **13**. * **Male Breast Cancer:** More strongly associated with **BRCA2** mutations than BRCA1. * **Triple Negative Breast Cancer (TNBC):** BRCA1 mutations are frequently associated with the basal-like (TNBC) subtype. * **Other Risk Factors:** Early menarche ( 55 years), HRT use, and atypical ductal hyperplasia (ADH).

Q: Which of the following statements is false regarding fibroadenoma?

It is not encapsulated.. ### Explanation **Fibroadenoma** is the most common benign tumor of the female breast, often referred to as the **"Breast Mouse"** due to its high mobility within the breast tissue. #### 1. Why Option D is the Correct (False) Statement Fibroadenoma is a **true benign neoplasm** that is **well-encapsulated**. On gross examination, it appears as a firm, lobulated, greyish-white mass with a distinct capsule that allows it to be easily "shelled out" during surgical excision (enucleation). Stating that it is not encapsulated is pathologically incorrect. #### 2. Analysis of Other Options * **Option A (Benign tumor):** This is true. It arises from the terminal duct lobular unit and involves both epithelial and stromal proliferation. It has no malignant potential in its simple form. * **Option B (Typically painless):** This is true. Fibroadenomas usually present as a painless, firm, and discrete lump. Pain is rare unless the tumor undergoes rapid growth (e.g., during pregnancy). * **Option C (Commonly occurs in young females):** This is true. The peak incidence is between **15–35 years** of age. It is considered an aberration of normal development and involution (ANDI). #### 3. NEET-PG High-Yield Clinical Pearls * **Mobility:** Its hallmark is extreme mobility within the breast parenchyma. * **Mammography:** Often shows a well-defined mass; in older women, it may show characteristic **"Popcorn calcification"** (due to involution). * **USG:** Usually shows a hypoechoic, well-circumscribed, oval mass with a horizontal orientation (wider than tall). * **Management:** Conservative management is preferred for small lesions ( 5 cm in diameter or >500g in weight.

Q: Breast cancer mainly spreads to the vertebrae via:

Batson's venous plexus. **Explanation:** **Correct Answer: C. Batson's venous plexus** The primary route for breast cancer metastasis to the vertebrae is through **Batson’s venous plexus**. This is a valveless, low-pressure network of veins that connects the deep pelvic veins and thoracic veins (including the intercostal veins) to the internal vertebral venous plexus. Because these veins lack valves, changes in intra-abdominal or intra-thoracic pressure (e.g., coughing or straining) can cause retrograde blood flow. This allows malignant cells from the breast to bypass the systemic circulation (cava and lungs) and seed directly into the spinal column and skull. **Analysis of Incorrect Options:** * **A. Arterial route:** While systemic spread can occur via arteries, it is not the primary or characteristic route for the early, localized vertebral metastasis seen in breast cancer. * **B. Direct invasion:** Breast cancer may invade the chest wall (pectoralis muscles), but it does not typically reach the posterior vertebral column through direct tissue extension. * **D. Axillary lymph nodes:** These are the primary site for **lymphatic** spread. While they are crucial for staging and prognosis, they do not provide a direct anatomical pathway to the vertebrae. **High-Yield Clinical Pearls for NEET-PG:** * **Batson’s Plexus** is also the reason why **Prostate Cancer** frequently metastasizes to the lumbar vertebrae. * The most common site of distant metastasis in breast cancer is **Bone** (specifically the spine, pelvis, and ribs). * The most common **organ** for metastasis is the **Lung** (via systemic venous drainage). * **Skip Metastasis:** Occasionally, breast cancer can spread to internal mammary nodes without involving axillary nodes, especially in medial quadrant tumors.

Q: Chronic treatment with tamoxifen can cause carcinoma of which organ?

Endometrium. **Explanation:** Tamoxifen is a **Selective Estrogen Receptor Modulator (SERM)**. Its mechanism of action is tissue-specific, acting as an estrogen **antagonist** in the breast but as an estrogen **agonist** in the uterus and bone. **Why Endometrium is correct:** In the postmenopausal uterus, tamoxifen exerts a pro-estrogenic effect on the endometrial lining. This leads to endometrial hyperplasia, polyp formation, and significantly increases the risk of **Endometrial Carcinoma** (specifically endometrioid adenocarcinoma). Patients on long-term tamoxifen therapy must be monitored for any abnormal vaginal bleeding. **Why other options are incorrect:** * **Ovary:** Tamoxifen does not have a significant agonistic effect on the ovarian epithelium. In fact, in premenopausal women, it may cause functional ovarian cysts, but it is not a recognized risk factor for ovarian carcinoma. * **Cervix & Vulva:** The estrogenic stimulatory effect of tamoxifen is specific to the endometrial lining. There is no clinical evidence linking tamoxifen use to an increased incidence of cervical or vulvar malignancies. **High-Yield Clinical Pearls for NEET-PG:** * **Dual Action:** Tamoxifen is the drug of choice for ER-positive breast cancer in both pre- and postmenopausal women. * **Bone Benefit:** Due to its agonistic effect on bone, it helps prevent postmenopausal osteoporosis. * **Lipid Profile:** It decreases LDL levels (beneficial). * **Adverse Effects:** Increased risk of **Thromboembolism** (DVT/PE) and **Cataracts**. * **Alternative:** In postmenopausal women, **Aromatase Inhibitors** (e.g., Anastrozole) are often preferred as they do not increase the risk of endometrial cancer.

Question 1

Which type of breast cancer has the best prognosis?

Accepted Answer

Mucinous carcinoma

Answer

Medullary carcinoma

Answer

Invasive ductal carcinoma

Answer

Lobular carcinoma

Question 2

Which of the following medications should NOT be given in cyclic mastalgia?

Accepted Answer

Estrogen

Answer

Evening primrose oil

Answer

Danazol

Answer

Tamoxifen

Question 3

Which of the following is an increased risk factor for carcinoma of the breast?

Accepted Answer

BRCA1 mutation

Answer

Breast feeding

Answer

Multiparity

Answer

Smoking

Question 4

Which of the following statements is false regarding fibroadenoma?

Accepted Answer

It is not encapsulated.

Answer

It is a benign tumor.

Answer

It is typically painless.

Answer

It commonly occurs in young females.

Question 5

What is an absolute contraindication for conservative breast cancer therapy?

Accepted Answer

History of previous radiation

Answer

Large pendulous breast

Answer

Axillary node involvement

Answer

Subareolar lump present

Question 6

Breast cancer mainly spreads to the vertebrae via:

Accepted Answer

Batson's venous plexus

Answer

Arterial route

Answer

Direct invasion

Answer

Axillary lymph nodes

Question 7

Chronic treatment with tamoxifen can cause carcinoma of which organ?

Accepted Answer

Endometrium

Answer

Ovary

Answer

Cervix

Answer

Vulva

Question 8

Which of the following statements about DCIS of the breast is true?

Accepted Answer

Rarely, DCIS can produce nipple discharge.

Answer

DCIS is a benign proliferation of epithelial cells.

Answer

DCIS involves only specific sectors of the breast.

Answer

DCIS is almost always detected histologically.

Question 9

True regarding breast carcinoma is:

Accepted Answer

Commoner in nulliparous women

Answer

Occurs most commonly in the upper outer quadrant

Answer

Early menarche and late menopause predispose for breast malignancy

Answer

Unrelated to family history of breast cancer

Question 10

Observation surgery is NOT advised in which of the following conditions?

Accepted Answer

Lobular carcinoma

Answer

Ductal carcinoma in situ

Answer

Early breast carcinoma

Answer

Screening detected carcinoma

Breast Surgery — MCQs

Breast Surgery — MCQs

On this page

Practice by Chapter

Want unlimited practice?